The FDA has granted accelerated approval to datopotamab deruxtecan (Datroway) for adults with locally advanced or metastatic non-small cell lung cancer that carries an EGFR mutation and has progressed.
Datopotamab deruxtecan, the first TROP2-directed therapy approved for lung cancer in the U.S., showed a 45% response rate in a subgroup from a phase 2 trial, with additional data from a phase 3 trial, according to a June 23 news release from the FDA.
Of 114 patients, 4.4% had a complete response and 40% had a partial response, with a median response of 6.5 months, according to a June 23 news release from the drugmaker.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
